Skip to main content

Advertisement

SpringerLink
Log in

Comparative efficacy of PD-1 inhibitors plus lenvatinib and regorafenib after lenvatinib failure for advanced hepatocellular carcinoma: a real-world study

  • Letter to the Editor
  • Published:
Hepatology International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Availability of data and materials

The dataset in the current study is available from the corresponding author on reasonable request.

References

  1. Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022;76(4):862–873

    Article  CAS  PubMed  Google Scholar 

  2. Hsu C, Rimassa L, Sun HC, Vogel A, Kaseb AO. Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Ther Adv Med Oncol 2021;13:17524123

    Article  Google Scholar 

  3. Zhang X, Wang J, Shi J, Jia X, Dang S, Wang W. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma. JAMA Netw Open 2021;4(4): e214846

    Article  PubMed  PubMed Central  Google Scholar 

  4. Patwala K, Prince DS, Celermajer Y, Alam W, Paul E, Strasser SI, et al. Lenvatinib for the treatment of hepatocellular carcinoma-a real-world multicenter Australian cohort study. Hepatol Int 2022;16(5):1170–1178

    Article  PubMed  Google Scholar 

  5. Zhao Y, Zhang YN, Wang KT, Chen L. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. BBA-Rev Cancer 2020;1874(1): 188391

    CAS  Google Scholar 

  6. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7(1):6

    Article  PubMed  Google Scholar 

  7. Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol 2020;38(26):2960–2970

    Article  PubMed  PubMed Central  Google Scholar 

  8. Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements. J HEPATOL 2020;72(2):288–306

    Article  PubMed  Google Scholar 

  9. Iwamoto H, Suzuki H, Shimose S, Niizeki T, Nakano M, Shirono T, et al. Weekends-Off lenvatinib for unresectable hepatocellular carcinoma improves therapeutic response and tolerability toward adverse events. Cancers 2020;12(4):1010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Morimoto M, Numata K, Kondo M, Kobayashi S, Ohkawa S, Hidaka H, et al. Field practice study of half-dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: a propensity score analysis. Hepatol Res 2015;45(3):279–287

    Article  CAS  PubMed  Google Scholar 

  11. Pfister D, Nunez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021;592(7854):450–456

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Cho H, Kang H, Lee HH, Kim CW. Programmed cell death 1 (PD-1) and cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4) in viral hepatitis. Int J Mol Sci 2017;18(7):1517

    Article  PubMed  PubMed Central  Google Scholar 

  13. Torrens L, Montironi C, Puigvehi M, Mesropian A, Leslie J, Haber PK, et al. Immunomodulatory effects of Lenvatinib plus anti-programmed cell death protein 1 in Mice and rationale for patient enrichment in hepatocellular carcinoma. Hepatology 2021;74(5):2652–2669

    Article  CAS  PubMed  Google Scholar 

  14. Yi C, Chen L, Lin Z, Liu L, Shao W, Zhang R, et al. Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC. Hepatology 2021;74(5):2544–2560

    Article  CAS  PubMed  Google Scholar 

  15. Wei CY, Zhu MX, Zhang PF, Huang XY, Wan JK, Yao XZ, et al. PKCalpha/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma. J Hepatol 2022;77(1):163–176

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank all the patients who were involved in this study.

Funding

This study was supported by the National Natural Science Foundation of China (No. 82172579, No. 81871985); Natural Science Foundation of Guangdong Province (No. 2018A0303130098, No. 2017A030310203); Science and Technology Planning Project of Guangdong Province (No. 2017A020215112); Medical Scientific Research Foundation of Guangdong Province (No. A2017477); Science and Technology Planning Project of Guangzhou (No. 201903010017, No. 201904010479); Clinical Trials Project (5010 Project) of Sun Yat-sen University (No. 5010–2017009).

Author information

Author notes

  1. Renguo Guan, Jie Mei and Shaohua Li share the first authorship.

Authors and Affiliations

  1. Department of Hepatobiliary Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, China

    Renguo Guan, Jie Mei, Shaohua Li, Wenping Lin, Min Deng, Wei Wei & Rongping Guo

  2. State Key Laboratory of Oncology in South China, Guangzhou, China

    Renguo Guan, Jie Mei, Shaohua Li, Wenping Lin, Min Deng, Wei Wei & Rongping Guo

  3. Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

    Renguo Guan, Jie Mei, Shaohua Li, Wenping Lin, Min Deng, Wei Wei & Rongping Guo

Authors
  1. Renguo Guan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jie Mei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shaohua Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wenping Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Min Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wei Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rongping Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by RG, JM and SL. The first draft of the manuscript was written by RG and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Wei Wei or Rongping Guo.

Ethics declarations

Conflict of interest

Renguo Guan, Jie mei, Shaohua Li, Wenping Lin, Min Deng, Wei Wei and Rongping Guo have no relevant financial or non-financial interests to disclose.

Ethical approval

All procedures followed were by the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Informed consent was obtained from all patients for being included in the study. The Institutional Review Board of the Ethics Committee of Sun Yat-Sen University Cancer Center approved this study.

Consent to participate

Written informed consent was obtained from the patients for their anonymized information to be published in this article.

Animal rights statement

This article does not contain any studies with animal subjects.

Permission to reproduce material from other sources

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guan, R., Mei, J., Li, S. et al. Comparative efficacy of PD-1 inhibitors plus lenvatinib and regorafenib after lenvatinib failure for advanced hepatocellular carcinoma: a real-world study. Hepatol Int 17, 765–769 (2023). https://doi.org/10.1007/s12072-022-10470-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-022-10470-0

Search

Navigation